With $200M in new cash, Syn­thego wants to be­come the man­u­fac­tur­ing bedrock for CRISPR. But where are its cus­tomers?

Af­ter near­ly a decade de­vel­op­ing CRISPR-based tools to help re­searchers in acad­e­mia and biotech run their ex­per­i­ments, Syn­thego is get­ting in­to a new game: man­u­fac­tur­ing.

The start­up, found­ed by two broth­ers with en­gi­neer­ing ex­pe­ri­ence but lit­tle bi­ol­o­gy back­ground and ad­vised by No­bel Prize win­ner Jen­nifer Doud­na, now says that it can help com­pa­nies as they try to push more and more CRISPR ther­a­pies in­to hu­man tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER